Vitamin D supplementation and sarcopenia

Vitamin D supplementation and muscle strength in sarcopenic elderly Lebanese people: A randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16665940

Enrollment

115

Registered

2018-02-20

Start date

2015-07-02

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia and Vitamin D Deficiency Nutritional, Metabolic, Endocrine Sarcopenia and Vitamin D Deficiency

Interventions

In this randomized, controlled, double blind study, participants are randomized (using the simple randomization method) to receive either a supplement of 10,000 IU of cholecalciferol (Euro-Pharm Inter

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Sarcopenic 2. Deficient in vitamin D 3. No medical history of type-2 diabetes 4. Age range of participants: 71-77

Exclusion criteria

Exclusion criteria: 1. Sarcopenic subjects 2. Incidence of balance problems due to neurological disorders 3. Renal failure 4. Congestive heart failure and acute heart insufficiency as well as uncontrolled arterial hypertension or hypotension 5. Use of sedative (that could affect balance) 6. Use of vitamin D supplementation 7. Primary hyperparathyroidism

Design outcomes

Primary

Measure	Time frame
1. Handgrip strength is measured using the Martin vigorimeter (Martin; Elmed, Addison, IL, USA), at baseline and 6 months. 2. Appendicular skeletal muscle mass is measured using bioimpedance analysis measurements (Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA) at baseline and 6 months. 3. 25 (OH)D levels are measured using radioimmunoassay (DiaSorin, Stillwater, MN) at baseline and 6 months	—

Measure

Time frame

1. Handgrip strength is measured using the Martin vigorimeter (Martin; Elmed, Addison, IL, USA), at baseline and 6 months. 2. Appendicular skeletal muscle mass is measured using bioimpedance analysis measurements (Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA) at baseline and 6 months. 3. 25 (OH)D levels are measured using radioimmunoassay (DiaSorin, Stillwater, MN) at baseline and 6 months

—

Secondary

Measure	Time frame
1. Weight is measured using the body composition analyzer (Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA) at baseline and 6 months 2. BMI is calculated using the standard formula (body weight in kilograms divided by square of body height in meters). at baseline and 6 months 3. Waist circumference is measured at the iliac crest at baseline and 6 months 4. Fat Mass is measured using the body composition analyzer (Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA) at baseline and 6 months 5. PTH is measured using a two-site immunoradiometric assay with an NH2-terminal monoclonal antibody as capture (Fitzgerald Industries International Inc., USA), at baseline and 6 months 6. Serum creatinine is measured using the Jaffe kineticalkaline picrate reaction (Interpretation and Techniques, Lea and Febiger, Philadelphia), at baseline and 6 months	—

Measure

Time frame

1. Weight is measured using the body composition analyzer (Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA) at baseline and 6 months 2. BMI is calculated using the standard formula (body weight in kilograms divided by square of body height in meters). at baseline and 6 months 3. Waist circumference is measured at the iliac crest at baseline and 6 months 4. Fat Mass is measured using the body composition analyzer (Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA) at baseline and 6 months 5. PTH is measured using a two-site immunoradiometric assay with an NH2-terminal monoclonal antibody as capture (Fitzgerald Industries International Inc., USA), at baseline and 6 months 6. Serum creatinine is measured using the Jaffe kineticalkaline picrate reaction (Interpretation and Techniques, Lea and Febiger, Philadelphia), at baseline and 6 months

—

Countries

Lebanon

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 4, 2026